靶向Neddylation修饰通路及通路抑制剂MLN4924的抗肺癌作用及其机制研究

doi:10.3760/cma.j.cn371439-20210517-00110

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (9): 564-567.doi: 10.3760/cma.j.cn371439-20210517-00110

靶向Neddylation修饰通路及通路抑制剂MLN4924的抗肺癌作用及其机制研究

朱峰, 王诗雯, 鲜敬荣, 刘越, 赵虎, 张艳梅()

复旦大学附属华东医院检验科 200040

收稿日期:2021-05-17 修回日期:2021-06-17 出版日期:2021-09-08 发布日期:2021-09-22
通讯作者: 张艳梅 E-mail:15618653286@163.com
基金资助:
国家自然科学基金(81902380);国家高技术研究发展计划(863计划)(2015AA021107-019);上海市科学技术委员会科研计划(18411960600);上海市科学技术委员会科研计划(18411950800);上海市“医苑新星”青年医学人才培养资助计划(2019-72)

Research on the anti-lung cancer effects of targeted Neddylation modifying pathway and its inhibitor MLN4924 and its mechanism

Zhu Feng, Wang Shiwen, Xian Jingrong, Liu Yue, Zhao Hu, Zhang Yanmei()

Department of Clinical Laboratory, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China

Received:2021-05-17 Revised:2021-06-17 Online:2021-09-08 Published:2021-09-22
Contact: Zhang Yanmei E-mail:15618653286@163.com
Supported by:
National Natural Science Foundation of China(81902380);National High-tech R&D Program of China(863 Program)(2015AA021107-019);Scientific Research Project of Shanghai Science and Technology Commission(18411960600);Scientific Research Project of Shanghai Science and Technology Commission(18411950800);Shanghai "Rising Stars of Medical Talent" Youth Development Program, Outstanding Youth Medical Talents(2019-72)

摘要/Abstract

摘要：

Neddylation修饰通路在肺癌中过度活化,可通过激活其底物CRL泛素连接酶活性诱导CRL抑癌蛋白底物降解,从而促进肺癌的发生发展。Neddylation修饰通路的小分子抑制剂MLN4924可以诱导肺癌细胞发生细胞周期阻滞、细胞凋亡和衰老,发挥抗肺癌作用。此外,通过靶向Neddylation修饰通路关键酶及其底物Cullin家族蛋白也可以抑制肺癌发生发展。

关键词: 肺肿瘤, 分子靶向治疗, Neddylation

Abstract:

Neddylation is overactivated in lung cancer, which promotes the development of lung cancer by activating its downstream CRL ubiquitin ligase and promoting the CRL tumor-suppressor protein substrate degradation. MLN4924, a small molecule inhibitor of Neddylation, plays an anti-lung cancer role by inducing cell cycle arrest, apoptosis and senescence. Furthermore, targeting the key enzymes of Neddylation and their substrates, Cullin family proteins, can inhibit the development of lung cancer.

Key words: Lung neoplasms, Molecular targeted therapy, Neddylation

朱峰, 王诗雯, 鲜敬荣, 刘越, 赵虎, 张艳梅. 靶向Neddylation修饰通路及通路抑制剂MLN4924的抗肺癌作用及其机制研究[J]. 国际肿瘤学杂志, 2021, 48(9): 564-567.

Zhu Feng, Wang Shiwen, Xian Jingrong, Liu Yue, Zhao Hu, Zhang Yanmei. Research on the anti-lung cancer effects of targeted Neddylation modifying pathway and its inhibitor MLN4924 and its mechanism[J]. Journal of International Oncology, 2021, 48(9): 564-567.

参考文献 32

[1]	明超, 何锐, 孙远, 等. lncRNA与小细胞肺癌[J]. 国际肿瘤学杂志, 2019, 46(10):620-623. DOI: 10.3760/cma.j.issn.1673-422X.2019.10.011. doi: 10.3760/cma.j.issn.1673-422X.2019.10.011
[2]	Xu Q, Lin G, Xu H, et al. MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells[J]. Oncol Lett, 2018, 15(1):515-521. DOI: 10.3892/ol.2017.7314. doi: 10.3892/ol.2017.7314
[3]	Ni S, Chen X, Yu Q, et al. Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth[J]. Eur J Med Chem, 2020, 185:111848. DOI: 10.1016/j.ejmech.2019.111848. doi: 10.1016/j.ejmech.2019.111848
[4]	Zhou L, Zhang W, Sun Y, et al. Protein neddylation and its alterations in human cancers for targeted therapy[J]. Cell Signal, 2018, 44:92-102. DOI: 10.1016/j.cellsig.2018.01.009. doi: 10.1016/j.cellsig.2018.01.009
[5]	Liang Y, Jiang Y, Jin X, et al. Neddylation inhibition activates the protective autophagy through NF-kappaB-catalase-ATF3 axis in human esophageal cancer cells[J]. Cell Commun Signal, 2020, 18(1):72. DOI: 10.1186/s12964-020-00576-z. doi: 10.1186/s12964-020-00576-z
[6]	Chen P, Hu T, Liang Y, et al. Neddylation inhibition activates the extrinsic apoptosis pathway through ATF4-CHOP-DR5 axis in human esophageal cancer cells[J]. Clin Cancer Res, 2016, 22(16):4145-4157. DOI: 10.1158/1078-0432.CCR-15-2254. doi: 10.1158/1078-0432.CCR-15-2254
[7]	Li L, Kang J, Zhang W, et al. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer[J]. EBioMedicine, 2019, 45:81-91. DOI: 10.1016/j.ebiom.2019.06.005. doi: 10.1016/j.ebiom.2019.06.005
[8]	Jiang Y, Cheng W, Li L, et al. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment[J]. Cell Biol Toxicol, 2020, 36(4):349-364. DOI: 10.1007/s10565-019-09503-6. doi: 10.1007/s10565-019-09503-6
[9]	Zhou L, Jiang Y, Liu X, et al. Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappaB-CCL2 signaling in lung cancer[J]. Oncogene, 2019, 38(29):5792-5804. DOI: 10.1038/s41388-019-0840-4. doi: 10.1038/s41388-019-0840-4
[10]	Zhou W, Xu J, Tan M, et al. UBE2M is a stress-inducible dual E2 for Neddylation and ubiquitylation that promotes targeted degradation of UBE2F[J]. Mol Cell, 2018, 70(6):1008-1024. e6. DOI: 10.1016/j.molcel.2018.06.002. doi: 10.1016/j.molcel.2018.06.002
[11]	Zhou W, Xu J, Li H, et al. Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage[J]. Clin Cancer Res, 2017, 23(4):1104-1116. DOI: 10.1158/1078-0432.CCR-16-1585. doi: 10.1158/1078-0432.CCR-16-1585
[12]	Li H, Tan M, Jia L, et al. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses Kras^G12D-driven lung tumorigenesis[J]. J Clin Invest, 2014, 124(2):835-846. DOI: 10.1172/JCI70297. doi: 10.1172/JCI70297
[13]	Zhao G, Gong L, Su D, et al. Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin beta1[J]. J Clin Invest, 2019, 129(3):972-987. DOI: 10.1172/JCI122779. doi: 10.1172/JCI122779
[14]	Hung MS, Chen IC, You L, et al. Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells[J]. J Cell Mol Med, 2016, 20(7):1295-1306. DOI: 10.1111/jcmm.12811. doi: 10.1111/jcmm.12811
[15]	Zhou J, Zhang S, Xu Y, et al. Cullin 3 overexpression inhibits lung cancer metastasis and is associated with survival of lung adenocarcinoma[J]. Clin Exp Metastasis, 2020, 37(1):115-124. DOI: 10.1007/s10585-019-09988-9. doi: 10.1007/s10585-019-09988-9
[16]	Ohta E, Itoh M, Ueda M, et al. Cullin-4B E3 ubiquitin ligase mediates Apaf-1 ubiquitination to regulate caspase-9 activity[J]. PLoS One, 2019, 14(7):e0219782. DOI: 10.1371/journal.pone.0219782. doi: 10.1371/journal.pone.0219782
[17]	Zhang H, Wang A, Tan Y, et al. NCBP1 promotes the development of lung adenocarcinoma through up-regulation of CUL4B[J]. J Cell Mol Med, 2019, 23(10):6965-6977. DOI: 10.1111/jcmm.14581. doi: 10.1111/jcmm.14581
[18]	Jia L, Yan F, Cao W, et al. Dysregulation of CUL4A and CUL4B ubiquitin ligases in lung cancer[J]. J Biol Chem, 2017, 292(7):2966-2978. DOI: 10.1074/jbc.M116.765230. doi: 10.1074/jbc.M116.765230
[19]	Mao H, Sun Y. Neddylation-independent activities of MLN4924[J]. Adv Exp Med Biol, 2020, 1217:363-372. DOI: 10.1007/978-981-15-1025-0_21. doi: 10.1007/978-981-15-1025-0_21
[20]	Lin S, Shang Z, Li S, et al. Neddylation inhibitor MLN4924 induces G₂ cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin[J]. Oncol Lett, 2018, 15(2):2583-2589. DOI: 10.3892/ol.2017.7616. doi: 10.3892/ol.2017.7616 pmid: 29434977
[21]	Cheng X, Ferrell JE Jr. Apoptosis propagates through the cytoplasm as trigger waves[J]. Science, 2018, 361(6402):607-612. DOI: 10.1126/science.aah4065. doi: 10.1126/science.aah4065
[22]	Wang Y, Luo Z, Pan Y, et al. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells[J]. Cancer Biol Ther, 2015, 16(3):420-429. DOI: 10.1080/15384047.2014.1003003. doi: 10.1080/15384047.2014.1003003
[23]	Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence[J]. Trends Cell Biol, 2018, 28(6):436-453. DOI: 10.1016/j.tcb.2018.02.001. doi: S0962-8924(18)30020-5 pmid: 29477613
[24]	Li L, Wang M, Yu G, et al. Overactivated neddylation pathway as a therapeutic target in lung cancer[J]. J Natl Cancer Inst, 2014, 106(6):dju083. DOI: 10.1093/jnci/dju083. doi: 10.1093/jnci/dju083
[25]	Wood EA, Lu Z, Jia S, et al. Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescence[J]. Vet Comp Oncol, 2020, 18(3):269-280. DOI: 10.1111/vco.12546. doi: 10.1111/vco.12546
[26]	Zhou L, Jiang Y, Luo Q, et al. Neddylation: a novel modulator of the tumor microenvironment[J]. Mol Cancer, 2019, 18(1):77. DOI: 10.1186/s12943-019-0979-1. doi: 10.1186/s12943-019-0979-1
[27]	Jiang Y, Liang Y, Li L, et al. Targeting neddylation inhibits intravascular survival and extravasation of cancer cells to prevent lung-cancer metastasis[J]. Cell Biol Toxicol, 2019, 35(3):233-245. DOI: 10.1007/s10565-019-09472-w. doi: 10.1007/s10565-019-09472-w
[28]	Lan H, Tang Z, Jin H, et al. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells[J]. Sci Rep, 2016, 6:24218. DOI: 10.1038/srep24218. doi: 10.1038/srep24218
[29]	Wei C, Yang C, Wang S, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circula-ting tumor cell-mediated colorectal cancer metastasis[J]. Mol Cancer, 2019, 18(1):64. DOI: 10.1186/s12943-019-0976-4. doi: 10.1186/s12943-019-0976-4
[30]	Kabir S, Cidado J, Andersen C, et al. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells[J]. Elife, 2019, 8:e44288. DOI: 10.7554/eLife.44288. doi: 10.7554/eLife.44288
[31]	Li H, Zhou W, Li L, et al. Inhibition of neddylation modification sensitizes pancreatic cancer cells to gemcitabine[J]. Neoplasia, 2017, 19(6):509-518. DOI: 10.1016/j.neo.2017.04.003. doi: 10.1016/j.neo.2017.04.003
[32]	Wang Y, Zhou Y, Zheng Z, et al. Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption[J]. Cell Death Dis, 2018, 9(11):1134. DOI: 10.1038/s41419-018-1174-9. doi: 10.1038/s41419-018-1174-9

靶向Neddylation修饰通路及通路抑制剂MLN4924的抗肺癌作用及其机制研究

Research on the anti-lung cancer effects of targeted Neddylation modifying pathway and its inhibitor MLN4924 and its mechanism

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[8]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[9]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[10]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[11]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[12]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[14]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.